Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Wave Life Sciences initiated a Phase 2a clinical trial evaluating its investigational RNA medicine WVE-007 in combination with tirzepatide for obesity treatment. Preclinical and emerging data indicate that WVE-007, utilizing GalNAc-siRNA technology, induces fat loss without muscle loss and could enhance weight loss beyond GLP-1 therapies alone. The…
TON Strategy Company is a leveraged, asymmetric play on the revival and market adoption of GRAM. For traders willing to accept high volatility and structural uncertainty, a modest long position around $1.20 with a tight stop and a $2.80 target offers a favorable risk-reward if token catalysts materialize over the next 45 trading days.
Nexentis Technologies Inc., through its wholly-owned subsidiary MitoCareX Bio Ltd., is evaluating additional commercially available approaches to obtain proteins for its in-vitro drug discovery research. This initiative aims to broaden research capabilities, increase flexibility, and support future discovery programs. The evaluation is in early sta…
Sprouts Farmers Market is trading roughly 41% below my fair value estimate of $118. The stock's recent pullback has pushed technicals into oversold territory while fundamentals - solid gross margins, positive new-store vintages and manageable valuation versus future earnings - argue for a rebound. This is a long trade idea with entry $69.50, stop $…
Biomea Fusion, a clinical-stage company focused on diabetes and obesity treatments, has terminated its proposed public offering of securities due to current market conditions deemed unfavorable for stockholders. No shares were sold, and the decision reflects management's commitment to protecting shareholder interests amid volatile markets.
DRDGOLD (DRD) is a niche surface-gold retreatment specialist trading at a modest multiple with a $2.31B market cap and 9.1x PE. With dividend income, improving technicals and rising short interest, the stock offers an asymmetric risk-reward for a long trade over the next 180 trading days as the company moves toward higher production in fiscal 2027.
Lexeo Therapeutics, a clinical stage biotech company focused on genetic diseases, announced its participation in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum scheduled for September 30, 2026. The event will be webcast live and later available for replay on the company's website.
AC Immune SA reported positive safety and immunogenicity data through week 100 in Part 1 of its VacSYn Phase 2 trial of ACI-7104 in early-stage Parkinson's disease patients. All primary endpoints—safety, tolerability, and immunogenicity—were met, with 100% of patients developing antibodies against the target. The trial showed strong antibody penetr…
Roivant announced that Immunovant's proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve statistical significance on its primary efficacy endpoint. Despite positive trends on secondary measures and a favorable safety profile, development for this indication will cease. Immunovant remains focused on advancing …
Oruka Therapeutics announced positive Week 28 data from the EVERLAST-A Phase 2a trial evaluating ORKA-001 in moderate-to-severe plaque psoriasis. Results show increasing skin clearance rates (PASI 100 up to 71.4%) months after the last dose at Week 4, with a strong safety and tolerability profile consistent with the IL-23p19 monoclonal antibody cla…
Avalo Therapeutics announced its participation in the upcoming European Academy of Dermatology and Venereology (EADV) 2026 Congress with a late-breaker oral presentation and poster showcasing the efficacy and safety data from its Phase 2 placebo-controlled LOTUS trial of abdakibart in treating moderate to severe hidradenitis suppurativa. The data p…
GXO Logistics has begun pilot deployments of a new Labor Management System (LMS) across major regions including North America and Europe. The LMS aims to standardize labor management globally, enhance workforce planning, improve operational efficiencies, and support the company's growth and profitability goals. Full-scale rollout is planned for 202…
Seer, Inc., a US-listed proteomics company, announced that Nanyang Technological University researchers will present early findings from the PRECISE-SG100K study at the 2026 HUPO World Congress. The study leverages Seer's Proteograph Product Suite combined with advanced mass spectrometry to deeply analyze the circulating proteome of 10,000 particip…
Immunovant announced topline results from its proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus (CLE). The study did not achieve statistical significance on the primary endpoint at 12 weeks. Despite positive trends in some secondary endpoints and a favorable safety profile, the company will discontinue development of IMVT…
Auddia Inc. announces the appointment of former U.S. Secretary of Defense Mark T. Esper to the board of LT350, a subsidiary of the pending merger that would form McCarthy Finney Inc. Esper's expertise enhances LT350’s positioning as a national security-aligned AI-edge computing company targeting commercial and defense markets. The merger, if comple…
Psyence Biomedical Ltd. announced a strategic investment of up to $5 million in PsyLabs alongside a reciprocal $9 million share exchange aimed at supporting the development and manufacturing capabilities of pharmaceutical-grade ibogaine. The company established Texas Ibogaine Research Corporation to facilitate clinical and regulatory activities for…
ANI Pharmaceuticals announced FDA approval of its generic Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg doses, a generic version of Afinitor Disperz®. This approval supports the company's strategy to launch multiple generics in 2026, with Everolimus alone representing $123 million in annual US sales. The move underscores ANI's strengt…
Take-Two Interactive (TTWO) trades in the pre-market at $206.90 as of September 23, 2026 at 6:30 AM EDT, reflecting expectations for a meaningful GTAVI-related rebound in revenue and earnings. Consensus forecasts put FY2027 revenue near $8.49 billion and EPS at $6.60, which equates to roughly a 31.8x forward P/E. Analysts project about 37 million G…
Oil prices fell back below the $100 per barrel mark as reports of quiet diplomacy at the United Nations sparked hopes for a de-escalation in the Iran conflict. Markets also digested signs of earlier-than-expected Saudi pipeline reopening, stronger demand in high-yield bond issuance, renewed AI optimism lifting semiconductor stocks, and a weak US pr…
U.S. Tiger Securities' analyst Bo Pei says Bitcoin has moved into a new bull-market phase and maintains a Buy rating with a $250,000 cycle price target to be achieved by 2029 or sooner. Pei points to a pattern of higher lows and highs, a recovery above key investor cost bases, and renewed exchange-traded fund demand as the main supporting signals. …
Morgan Stanley has refreshed its assessment of how European sectors and individual stocks could react if the Strait of Hormuz reopens, citing growing US-Iran diplomatic engagement and expectations for an earlier restart of Saudi Arabia's East-West pipeline. The firm highlights 50 stocks most positively correlated with a reopening, identifies the se…
Hagerty is trading near fresh highs as its Broad Arrow auctions and marketplace execution keep revenue mix diversifying. Strong free cash flow, reasonable price-to-sales and a falling short interest backdrop support a mid‑term long. Trade plan included with entry, stop and target for a 45 trading day horizon.
Mediated shuttle talks between Iranian and US representatives on the sidelines of the UN General Assembly have raised cautious optimism about possible progress toward ending the Middle East war. The contacts were conducted through intermediaries and did not reflect a direct meeting between delegations. Meanwhile, continued conflict and shipping dis…
Surgery Partners (SGRY) looks attractive after a reported Idaho Falls asset divestment that should modestly improve leverage and free up capital. At $15.85, the shares trade below prior peaks, have improving technical momentum, and sit at a valuation that discounts operating leverage and higher rates. This trade targets $20.00 with a $13.50 stop on…
Highlander Silver Corp. has executed a mandate letter with Natixis Corporate & Investment Banking to lead a fully underwritten $330 million senior secured project finance facility for the development and construction of its Corani Silver Project in Peru. The financing includes a $100 million cost overrun facility and is expected to close in Q1 2027…
